Scholars@Duke
Lauren Covert

Lauren Covert

Assistant Professor of Pediatrics
Pediatrics, Rheumatology

Scholarly Works

Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis.

Conference Clin Exp Rheumatol · February 2026 OBJECTIVES: We performed a multi-institutional retrospective review of patients treated for juvenile dermatomyositis (JDM)-associated calcinosis to analyse the association between treatment outcomes and patient, disease, and treatment characteristics. METH ... Full text Link to item Cite

Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis

Journal article CLINICAL AND EXPERIMENTAL RHEUMATOLOGY · February 2026 Link to item Cite

Interferon-β-Induced Injury During Pediatric Muscle Differentiation: Insight Into Juvenile Dermatomyositis Pathogenesis.

Journal article ACR Open Rheumatol · January 2025 OBJECTIVE: Juvenile dermatomyositis (JDM) involves up-regulated type I interferons (IFNs), including IFNβ, yet pathologic mechanisms remain poorly understood. We aimed to characterize the functional and structural effects of IFNβ on in vitro human pediatri ... Full text Open Access Link to item Cite

Unmasking inflammation in juvenile dermatomyositis: myokine profiles of patients and bioengineered human muscle.

Journal article Front Immunol · 2025 INTRODUCTION: Juvenile dermatomyositis (JDM), a rare autoimmune disease characterized by a type I interferon (IFN) gene signature and muscle weakness, lacks robust biomarkers and disease models. Myokines-muscle-derived cytokines-are potential biomarkers an ... Full text Open Access Link to item Cite

Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis.

Journal article Rheumatology (Oxford) · September 1, 2024 OBJECTIVE: To better understand the pathogenesis of juvenile dermatomyositis (JDM), we examined the effect of the cytokines type I interferons (IFN I) and JAK inhibitor drugs (JAKi) on gene expression in bioengineered pediatric skeletal muscle. METHODS: My ... Full text Open Access Link to item Cite

Effect of type I interferon on engineered pediatric skeletal muscle: a promising model for juvenile dermatomyositis.

Journal article Rheumatology (Oxford) · January 4, 2024 OBJECTIVE: To investigate pathogenic mechanisms underlying JDM, we defined the effect of type I IFN, IFN-α and IFN-β, on pediatric skeletal muscle function and expression of myositis-related proteins using an in vitro engineered human skeletal muscle model ... Full text Open Access Link to item Cite

Transitioning to Adulthood with a Rheumatic Disease: A Case-Based Approach for Rheumatology Care Teams.

Journal article Rheum Dis Clin North Am · February 2022 Both pediatric and adult rheumatology care teams play a central role in health care transition, the shift from child- and family-centered to adult-oriented health care. Components of transition preparation include readiness assessment, setting self-managem ... Full text Open Access Link to item Cite

Comprehensive Management of Rheumatic Diseases Affecting the Temporomandibular Joint.

Journal article Diagnostics (Basel) · February 27, 2021 The temporomandibular joint (TMJ) is a synovial joint and thus is vulnerable to the afflictions that may affect other joints in the fields of rheumatology and orthopedics. Too often temporomandibular complaints are seen strictly as dental or orofacial conc ... Full text Open Access Link to item Cite